PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value
$63.49+0.13 (+0.21%)
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
PTC Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
PTC Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -9.2%. For fiscal 2025 it was 39.4%, against -45.0% the year before. The highest annual figure on record is 39.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.4% | +84.5 |
| FY2024 | Dec 31, 2024 | -45.0% | +21.8 |
| FY2023 | Dec 31, 2023 | -66.8% | +13.2 |
| FY2022 | Dec 31, 2022 | -80.0% | +17.3 |
| FY2021 | Dec 31, 2021 | -97.3% | +17.8 |
| FY2020 | Dec 31, 2020 | -115.1% | −33.1 |
| FY2019 | Dec 31, 2019 | -82.0% | −33.6 |
| FY2018 | Dec 31, 2018 | -48.4% | −7.7 |
| FY2017 | Dec 31, 2017 | -40.6% | +131.2 |
| FY2016 | Dec 31, 2016 | -171.8% | +291.8 |
| FY2015 | Dec 31, 2015 | -463.6% | −92.2 |
| FY2014 | Dec 31, 2014 | -371.4% | −222.7 |
| FY2013 | Dec 31, 2013 | -148.6% | −71.4 |
| FY2012 | Dec 31, 2012 | -77.3% | −106.6 |
| FY2011 | Dec 31, 2011 | 29.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -14.4% | −22.0 |
| Q2 FY2026 | Jun 30, 2026 | 23.2% | +59.4 |
| Q1 FY2026 | Mar 31, 2026 | -1.0% | −74.7 |
| Q4 FY2025 | Dec 31, 2025 | -82.0% | −51.0 |
| Q3 FY2025 | Sep 30, 2025 | 7.5% | +61.7 |
| Q2 FY2025 | Jun 30, 2025 | -36.3% | +16.9 |
| Q1 FY2025 | Mar 31, 2025 | 73.7% | +117.3 |
| Q4 FY2024 | Dec 31, 2024 | -30.9% | +19.8 |
| Q3 FY2024 | Sep 30, 2024 | -54.2% | +13.4 |
| Q2 FY2024 | Jun 30, 2024 | -53.1% | +39.9 |
| Q1 FY2024 | Mar 31, 2024 | -43.6% | +19.5 |
| Q4 FY2023 | Dec 31, 2023 | -50.7% | +51.3 |
| Q3 FY2023 | Sep 30, 2023 | -67.6% | −17.3 |
| Q2 FY2023 | Jun 30, 2023 | -93.0% | −1.1 |
| Q1 FY2023 | Mar 31, 2023 | -63.1% | +22.1 |
| Q4 FY2022 | Dec 31, 2022 | -102.1% | −15.4 |
| Q3 FY2022 | Sep 30, 2022 | -50.3% | +46.0 |
| Q2 FY2022 | Jun 30, 2022 | -91.9% | +9.6 |
| Q1 FY2022 | Mar 31, 2022 | -85.2% | +23.9 |
| Q4 FY2021 | Dec 31, 2021 | -86.7% | −24.2 |
| Q3 FY2021 | Sep 30, 2021 | -96.3% | −37.5 |
| Q2 FY2021 | Jun 30, 2021 | -101.5% | +139.7 |
| Q1 FY2021 | Mar 31, 2021 | -109.1% | +56.0 |
| Q4 FY2020 | Dec 31, 2020 | -62.6% | +18.0 |
| Q3 FY2020 | Sep 30, 2020 | -58.9% | +25.2 |
| Q2 FY2020 | Jun 30, 2020 | -241.1% | −192.3 |
| Q1 FY2020 | Mar 31, 2020 | -165.1% | −30.5 |
| Q4 FY2019 | Dec 31, 2019 | -80.5% | −24.2 |
| Q3 FY2019 | Sep 30, 2019 | -84.0% | +11.1 |
| Q2 FY2019 | Jun 30, 2019 | -48.9% | −35.0 |
| Q1 FY2019 | Mar 31, 2019 | -134.6% | −100.2 |
| Q4 FY2018 | Dec 31, 2018 | -56.3% | −58.5 |
| Q3 FY2018 | Sep 30, 2018 | -95.1% | −14.4 |
| Q2 FY2018 | Jun 30, 2018 | -13.8% | +22.6 |
| Q1 FY2018 | Mar 31, 2018 | -34.4% | +75.5 |
| Q4 FY2017 | Dec 31, 2017 | 2.2% | +108.9 |
| Q3 FY2017 | Sep 30, 2017 | -80.8% | – |
| Q2 FY2017 | Jun 30, 2017 | -36.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -109.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -106.7% | – |
See a number that looks wrong?